In January 2026, NICA urged congressional leadership to advance pharmacy benefit manager (PBM) reform provisions included in the Consolidated Appropriations Act of 2026. NICA highlighted concerns about PBM consolidation, rising patient out-of-pocket costs, and anticompetitive business practices. The letter supported reforms to increase pricing transparency, require manufacturer rebates to be passed on to employers, and eliminate compensation structures that incentivize higher drug prices.
January 21, 2026
| The Honorable Mike Johnson Speaker U.S. House of Representatives Washington, DC 20515 | The Honorable John Thune Majority Leader U.S. Senate Washington, DC 20510 |
| The Honorable Hakeem Jeffries Minority Leader U.S. House of Representatives Washington, DC 20515 | The Honorable Chuck Schumer Minority Leader U.S. Senate Washington, DC 20510 |
Re: Consolidated Appropriations Act of 2026 – Support PBM Reform Provisions
Majority Leader Thune, Speaker Johnson, Leader Schumer, and Leader Jeffries:
The National Infusion Center Association (NICA) is a nonprofit organization formed to support non-hospital, community-based infusion centers caring for patients in need of provider-administered medications. To improve access to medical benefit drugs that treat complex, rare, and chronic diseases, we work to ensure that patients can access these drugs in safe, more efficient, and cost-effective alternatives to hospital care settings. NICA supports policies that improve drug affordability for beneficiaries, increase price transparency, reduce disparities in safety across care settings, and foster patient access to the highest-quality, lowest-cost setting.
NICA strongly supports policies that address the anticompetitive and harmful business practices of Pharmacy Benefit Managers (PBMs) and urges Congress to advance the PBM reform policies currently included within the Consolidated Appropriations Act of 2026, which will protect patients and ensure access to care.
Over the last decade, the PBM industry has seen considerable consolidation, which was recently noted by the Federal Trade Commission. [1] The contractual posture that formerly existed when the insurer and the PBM were distinct entities has disappeared through mergers – Express Scripts is a subsidiary of Cigna, CVS Caremark is a subsidiary of CVS Health, and OptumRX is a UnitedHealth Group subsidiary. Historically, insurers and employers were considered clients of PBMs. However, due to extensive vertical integration within the industry, the relationship between insurers and PBMs has evolved to a mutualistic relationship. Together, these three PBMs cover over 260 million patients, amounting to control over three quarters of the prescription drug market in the United States.[2]
Consolidation in the market has made it difficult to negotiate with these entities. More concerning is the impact on patients, who find themselves vulnerable when their insurance providers and PBMs prioritize profits over patient savings. While PBMs excel at securing discounts, these cost reductions rarely translate into lower out-of-pocket expenses for patients. The drug pricing and premium trends over the last decade demonstrate that whatever savings PBMs negotiate are mostly absorbed by the PBMs themselves – not the patient. In fact, for every rebated dollar, the list price of the medication increases by $1.17.[3] That hurts the patient, who typically pays coinsurance on the list price before rebates are applied.
This is why comprehensive PBM reform is needed now. NICA supports the following PBM reform provisions included within the Consolidated Appropriations Act of 2026:
- Require manufacturer rebates to be passed on directly to the employer, offering immediate savings for employee health plans
- Require PBM payments to only be derived from flat dollar amounts and not based on coverage or formulary placement
- Improve transparency by requiring mandatory reporting
Some manufacturers offer significant rebates for their medications. Unfortunately, most price concessions do not translate into savings for employers or patients, but are retained by the PBM itself.[4] Thus, these rebates currently fail to have the full impact on patient out-of-pocket costs. Instead, NICA supports policies that allow these rebates to be passed on directly to the employer so they experience immediate savings that can in turn be passed on to their employees through more robust coverage or cheaper health plan contributions.
Several “transparent” PBMs have disrupted the market by adjusting their fee structures to collect a flat dollar amount instead of a percentage of the drug’s list price. This removes the incentive for PBMs to prefer high-cost drugs over lower cost medications simply due to the PBM’s percentage-based compensation. NICA supports policies that require PBMs to remove coverage determinations and formulary placement from the PBM’s fee structure and instead base compensation on flat dollar amounts.
It is very clear that PBMs and their vertically integrated subsidiaries operate in a vacuum in which none of the other parties– including ambulatory infusion centers – have access to information on how these drug pricing decisions are made. With an entirely consolidated vertical supply chain, tracing money within the business model becomes nearly impossible. Improved reporting and transparency are necessary to improve our understanding of drug prices and should be included within any PBM reform package.
The current pricing system is not serving patients in need of prescription drugs, and it is particularly harmful for patients on infused specialty medications that can be quite expensive due to their complexity. The business practices of pharmacy benefit managers are driving higher out-of-pocket costs for patients, formulary design that encourages the use of expensive drugs over lower-cost alternatives, and utilization management that results in delayed and even denied access to care. NICA urges Congress to address these harmful and anticompetitive business practices within the Consolidated Appropriations Act of 2026, and protect patients who deserve lower out-of-pocket costs, greater drug access and improved transparency.
Thank you for the opportunity to comment on this important issue. Should you have any questions, please contact [email protected].
Sincerely,

Brian Nyquist, MPH
Chief Executive Officer
National Infusion Center Association
[1] Federal Trade Commission, “Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies” (July 2024).
[2] Health Affairs, Health Policy Brief, “Pharmacy Benefit Managers” (Sept. 14, 2017).
[3] The Association Between Drug Rebates and List Prices, Neeraj Sood, PhD, Rocio Ribero, PhD, Martha Ryan, and Karen Van Nuys, PhD, University of Southern California, Leonard D. Schaeffer Center for Health Policy & Economics (Feb. 11 2020).
[4] Annals of Health Law, “Squeezing the Middlemen: Ending Underhanded Dealing in the Pharmacy Benefit Management Industry Through Regulation” 20 Annals of Health Law 77, 82 (2011).

